Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech [Seeking Alpha]
Precigen (NASDAQ:PGEN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]